[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-eye-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-eye-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,76,101,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100591230","phase-1-a-study-to-assess-adverse-events-how-the-drug-moves-through-the-body-and-effectiveness-of-intravenous-infusions-of-abbv-319-in-adult-participants-with-systemic-lupus-erythematosus-sle-and-sjogrens-disease-sjd-100591230",false,"NCT06977724","A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)","A Phase1b, Multiple Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Safety, and Efficacy of ABBV-319 in Subjects With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)","Inclusion Criteria:\n\n* Systemic Lupus Erythematosus (SLE) Population - Clinical diagnosis of SLE at least 6 months prior to Screening as defined by the 2019 European Alliance of Associations for Rheumatology (EULAR)\u002FAmerican College Of Rheumatology (ACR) classification criteria for SLE and a positive antinuclear antibody (ANA) \\>= 1:80 drawn at Screening.\n* SLE Population - Presence of anti-double stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or anti-Sjogren's syndrome Ag A (SSA) Abs above the upper limit of normal (ULN).\n* Sjogren's Disease (SjD) Population - Primary diagnosis of SjD at least 6 months prior to Screening as defined by the ACR\u002FEULAR 2016 Criteria.\n* SjD Population - EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) \\>= 5 at Screening.\n* SjD Population - EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) \\>= 5 at Screening.\n\nExclusion Criteria:\n\n* History of infection as defined in the protocol.\n* Any of the medical diseases or disorders listed in the protocol.\n* History of clinically significant (per investigator's judgment) drug or alcohol abuse within the 6 months prior to Screening.\n* Any planned elective surgery that would impact study procedures or assessments through the completion of the Day 365 assessments.\n* Any clinically significant ECG abnormalities at Screening.","ALL","18 Years","75 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity and Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement. ABBV-319 exhibits potential B cell depletion in SLE and SjD which are characterized by B cell hyperactivity. The purpose of this study is to assess the pharmacokinetics, safety, and efficacy of ABBV-319 in adult participants with SLE or SjD.\n\nABBV-319 is an investigational drug being developed for the treatment of SLE and SjD. Participants are placed in 1 of 6 groups called treatment arms. Each group receives a different dose of ABBV-319 depending on whether they have SLE or SjD. Around 36 adult participants with SLE or SjD will be enrolled at approximately 10 sites worldwide.\n\nParticipants will receive 2 doses of IV ABBV-319 21 days apart and will be followed for up to 343 days.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[27,28],"Dry Eye Syndrome","Systemic Lupus Erythematosus",[27,28,30],"ABBV-319","RECRUITING","2026-05-15",{"date":34,"type":35},"2026-05-19","ACTUAL",{"date":37,"type":35},"2025-08-26",{"date":39,"type":21},"2029-03",{"name":41,"class":42},"AbbVie","INDUSTRY",7,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100377761","proteomic-and-metabolomic-lacrimal-fingerprint-in-diverse-pathologies-of-the-ocular-surface-100377761","NCT04198740","Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface","EML-MSO","Inclusion Criteria:\n\n* Patients with healthy corneas or suffering from one of these pathologies:\n\nDry eye syndrome; Infectious keratitis and\u002For conjunctivitis; Mucous membrane pemphigoid; Allergic conjunctivitis.\n\nExclusion Criteria:\n\n* Patients younger than 18 years old;\n* Patients incapable of giving informed consent.",true,{"count":53,"type":21},300,"OBSERVATIONAL","This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.",[27,57,58,59],"Infectious Keratoconjunctivitis","Mucous Membrane Pemphigoid","Allergic Conjunctivitis",[61,62,63,64],"Lacrimal fingerprint","Metabolomics","Proteomics","Ocular surface","2026-04-23",{"date":67,"type":35},"2026-04-27",{"date":69,"type":35},"2020-02-01",{"date":71,"type":21},"2035-01",{"name":73,"class":74},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100615675","autologous-serum-eye-drops-in-dry-eye-syndrome-100615675","NCT07295691","Autologous Serum Eye Drops in Dry Eye Syndrome","Autologous Serum Eye Drops in Dry Eye Syndrome: Clinical Efficacy and Safety Evaluation","Inclusion Criteria:\n\n* Children aged less than 18 years.\n* Both sexes.\n* Diagnosed with moderate to severe dry eye syndrome (DES) refractory to artificial tears.\n\nExclusion Criteria:\n\n* Active ocular infection.\n* Recent ocular surgery.\n* Systemic immunosuppressive therapy.\n* History of allergy to blood-derived products.",{"count":84,"type":21},70,[86],"NA","This study aims to evaluate the clinical efficacy and safety of autologous serum eye drops (ASEDs) in patients with moderate-to-severe dry eye syndrome who are refractory to conventional artificial tear therapy.",[89,27],"Autologous Serum Eye Drops","2025-12-06",{"date":92,"type":35},"2025-12-22",{"date":94,"type":35},"2025-09-01",{"date":96,"type":21},"2025-12-31",{"name":98,"class":99},"The General Authority for Teaching Hospitals and Institutes","NETWORK",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":51,"sex":16,"minAge":108,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":100},"100552587","exosome-mirna-and-transcriptome-profiling-of-dry-eye-syndrome-and-sjogrens-syndrome-100552587","NCT06475027","Exosome-miRNA and Transcriptome Profiling of Dry Eye Syndrome and Sjogren's Syndrome","Systematic Dissection of Exosome-miRNA and Transcriptome Profiling of Dry Eye Syndrome and Sjogren's Syndrome for Alleviating the Sicca Symptoms","Dry eye syndrome\n\n* Inclusion Criteria: aged between 20 and 75 years Schirmer's test less than 10 mm\u002F5 min\n* Exclusion Criteria: Pregnancy With eye inflammation or infectious eye disease Accepted operation of eye\n\nSjögren's syndrome\n\n* Inclusion Criteria: primary or secondary SS aged between 20 and 75 years fulfilled the 2002 American-European Consensus Criteria for SS (AECG) had no abnormal findings of immune, liver, kidney, or blood function evaluations.\n* Exclusion Criteria: a history of alcohol abuse, diabetes mellitus, or major life-threatening condition pregnancy or breastfeeding steroid pulse therapy within three months prior to the commencement of our study.\n\nnon AIDDES Healthy Controls\n\n* Inclusion Criteria: aged between 20 and 75 years without any Chronic disease\n* Exclusion Criteria: any Sjögren's syndrome or Dry eye syndrome.","20 Years",{"count":110,"type":21},220,"This study combines data from two trials testing acupuncture (ACUDES) and a Chinese herbal tea bag TBDESJS for Dry Eye Syndrome and Sjögren's syndrome. Both treatments improved tear production. Researchers will now analyze participants' blood remaining samples and other data to understand how these therapies work. They will use advanced methods to identify tiny RNA molecules and immune system activity. This integrated approach aims to explain how acupuncture and TBDESJS improve dryness and support their use in managing these conditions.",[27,113,114],"Sjogren's Syndrome","Xerophthalmia",[116,117,114,118,119,120,121,122],"Dry eye syndrome","Sjögren's syndrome","Acupuncture","Exosome","transcriptome","GB20","BL2","NOT_YET_RECRUITING","2024-06-20",{"date":126,"type":35},"2024-06-26",{"date":128,"type":21},"2024-07-01",{"date":130,"type":21},"2026-12-31",{"name":132,"class":133},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":51,"sex":16,"minAge":108,"maxAge":18,"enrollmentInfo":141,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":100},"100357757","dry-eye-syndrome-healthy-control-sjgrens-syndrome-and-other-inflammation-disease-in-taiwan-biobank-100357757","NCT03938207","Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank","The Comprehensive Analysis of Health Records, TCM Constitution, Biomarker, and Whole-genome Sequencing Among Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan","Sjögren's syndrome\n\nInclusion Criteria:\n\n1. aged between 20 and 75 years\n2. fulfilled the 2002 American-European Consensus Criteria for SS (AECG) Exclusion Criteria: NA\n\nDry eye syndrome\n\nInclusion Criteria:\n\n1. aged between 20 and 75 years\n2. Schirmer's test less than 10 mm\u002F5 min Exclusion Criteria: NA\n\nInflammation disease\n\nInclusion Criteria:\n\n1. aged between 20 and 75 years\n2. Disease diagnosed with Inflammation Exclusion Criteria: NA",{"count":142,"type":21},100000,"The comprehensive analysis of health records, TCM constitution, biomarker, and whole-genome sequencing among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease in Taiwan: an integrated analysis between Taiwan Biobank and Sjögren's syndrome Database",[27,113,145,146],"Healthy Control","Inflammation",[116,117,148,114,149,146,150],"Gene modulation","TCM pattern","Healthy control","2022-08-09",{"date":153,"type":35},"2022-08-11",{"date":155,"type":21},"2022-10-01",{"date":157,"type":21},"2027-12-31",{"name":132,"class":133}]